FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202951072> ?p ?o ?g. }

• W3202951072 endingPage "439" @default.
• W3202951072 startingPage "429" @default.
• W3202951072 abstract "Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast-acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance.To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus.Thirty-four patients with mild-to-moderate pemphigus vulgaris or foliaceus were enrolled in an open-label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg-1 intravenously with various dosing frequencies, as monotherapy or as add-on therapy to low-dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058).Adverse events were mostly mild and were reported by 16 of 19 (84%) patients receiving efgartigimod 10 mg kg-1 and 13 of 15 (87%) patients receiving 25 mg kg-1 , with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti-desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg kg-1 per day (range 0·06-0·48) led to complete clinical remission in 14 of 22 (64%) patients within 2-41 weeks.Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus." @default.
• W3202951072 created "2021-10-11" @default.
• W3202951072 creator A5008381456 @default.
• W3202951072 creator A5015639850 @default.
• W3202951072 creator A5017692169 @default.
• W3202951072 creator A5017978198 @default.
• W3202951072 creator A5032161541 @default.
• W3202951072 creator A5050985511 @default.
• W3202951072 creator A5059918892 @default.
• W3202951072 creator A5062770314 @default.
• W3202951072 creator A5063107524 @default.
• W3202951072 creator A5067198663 @default.
• W3202951072 creator A5076078511 @default.
• W3202951072 creator A5080267053 @default.
• W3202951072 creator A5089231402 @default.
• W3202951072 creator A5090243014 @default.
• W3202951072 date "2021-11-28" @default.
• W3202951072 modified "2023-10-17" @default.
• W3202951072 title "Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*" @default.
• W3202951072 cites W1495622219 @default.
• W3202951072 cites W1529000609 @default.
• W3202951072 cites W1636327287 @default.
• W3202951072 cites W1991918063 @default.
• W3202951072 cites W2003362843 @default.
• W3202951072 cites W2006779897 @default.
• W3202951072 cites W2019808150 @default.
• W3202951072 cites W2024972268 @default.
• W3202951072 cites W2035464330 @default.
• W3202951072 cites W2057412944 @default.
• W3202951072 cites W2061641422 @default.
• W3202951072 cites W2066413131 @default.
• W3202951072 cites W2096463706 @default.
• W3202951072 cites W2122715855 @default.
• W3202951072 cites W2127401827 @default.
• W3202951072 cites W2140543357 @default.
• W3202951072 cites W2142709180 @default.
• W3202951072 cites W2144759405 @default.
• W3202951072 cites W2419038595 @default.
• W3202951072 cites W25755508 @default.
• W3202951072 cites W2601272633 @default.
• W3202951072 cites W2602517913 @default.
• W3202951072 cites W2771233382 @default.
• W3202951072 cites W2787771368 @default.
• W3202951072 cites W2883123810 @default.
• W3202951072 cites W2890433091 @default.
• W3202951072 cites W2944937742 @default.
• W3202951072 cites W2994780695 @default.
• W3202951072 cites W2995726856 @default.
• W3202951072 cites W3080818382 @default.
• W3202951072 cites W3130798483 @default.
• W3202951072 cites W3169359442 @default.
• W3202951072 cites W4206388858 @default.
• W3202951072 cites W4210972925 @default.
• W3202951072 doi "https://doi.org/10.1111/bjd.20782" @default.
• W3202951072 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34608631" @default.
• W3202951072 hasPublicationYear "2021" @default.
• W3202951072 type Work @default.
• W3202951072 sameAs 3202951072 @default.
• W3202951072 citedByCount "33" @default.
• W3202951072 countsByYear W32029510722021 @default.
• W3202951072 countsByYear W32029510722022 @default.
• W3202951072 countsByYear W32029510722023 @default.
• W3202951072 crossrefType "journal-article" @default.
• W3202951072 hasAuthorship W3202951072A5008381456 @default.
• W3202951072 hasAuthorship W3202951072A5015639850 @default.
• W3202951072 hasAuthorship W3202951072A5017692169 @default.
• W3202951072 hasAuthorship W3202951072A5017978198 @default.
• W3202951072 hasAuthorship W3202951072A5032161541 @default.
• W3202951072 hasAuthorship W3202951072A5050985511 @default.
• W3202951072 hasAuthorship W3202951072A5059918892 @default.
• W3202951072 hasAuthorship W3202951072A5062770314 @default.
• W3202951072 hasAuthorship W3202951072A5063107524 @default.
• W3202951072 hasAuthorship W3202951072A5067198663 @default.
• W3202951072 hasAuthorship W3202951072A5076078511 @default.
• W3202951072 hasAuthorship W3202951072A5080267053 @default.
• W3202951072 hasAuthorship W3202951072A5089231402 @default.
• W3202951072 hasAuthorship W3202951072A5090243014 @default.
• W3202951072 hasBestOaLocation W32029510721 @default.
• W3202951072 hasConcept C126322002 @default.
• W3202951072 hasConcept C159654299 @default.
• W3202951072 hasConcept C16005928 @default.
• W3202951072 hasConcept C163764329 @default.
• W3202951072 hasConcept C197934379 @default.
• W3202951072 hasConcept C203014093 @default.
• W3202951072 hasConcept C2777288759 @default.
• W3202951072 hasConcept C2778720950 @default.
• W3202951072 hasConcept C2778862538 @default.
• W3202951072 hasConcept C2779075594 @default.
• W3202951072 hasConcept C2779134260 @default.
• W3202951072 hasConcept C2781313415 @default.
• W3202951072 hasConcept C2781327288 @default.
• W3202951072 hasConcept C2910519024 @default.
• W3202951072 hasConcept C71924100 @default.
• W3202951072 hasConcept C90924648 @default.
• W3202951072 hasConceptScore W3202951072C126322002 @default.
• W3202951072 hasConceptScore W3202951072C159654299 @default.
• W3202951072 hasConceptScore W3202951072C16005928 @default.
• W3202951072 hasConceptScore W3202951072C163764329 @default.

• next